Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México

Molina-Salazar, Raúl E.; Rivas-Vilchis, José Federico

doi:10.1590/s0102-311x1998000300006

Cited by 4 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in the late 90’s showed that about half of essential medicines were available in public healthcare facilities [13] reporting that lack of financial resources, inefficient procurement planning and distribution contributed to the unavailability of medicines [12, 13]. Other studies showed how prices of branded medicines in Mexico exceeded those in international markets [11]. …”

Section: Introductionmentioning

confidence: 99%

Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country

et al. 2017

View full text Add to dashboard Cite

BackgroundThe World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the approach that the Mexican government has taken to improve availability and affordability of essential medicines.MethodsDescriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis of publicly available data and health progress reports, with a focus on availability and affordability of medicines.ResultsThe government has implemented pooled procurement, price negotiations, and an information platform in the public sector to improve affordability and availability. The government mainly reports on the savings that these strategies have generated in the public expenditure but their full impact on availability and affordability has not been assessed.ConclusionsTo increase availability and affordability of medicines in the public sector, the Mexican government has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information, other policy components and pricing interventions are needed. All these strategies should be included in a comprehensive NPP.

show abstract

Section: Introductionmentioning

confidence: 99%

Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country

et al. 2017

View full text Add to dashboard Cite

show abstract

The fuzzy line between needs, coverage, and excess in the Mexican Formulary List: an example of qualitative market width analysis

Rico-Alba

Figueras

2012

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Drug Regulation and Control in Nigeria: the Challenge of Counterfeit Drugs

Erhun¹,

Babalola²,

M.O.³

2013

whp

View full text Add to dashboard Cite

The primary objective of this study is to establish the factors that have contributed to the preponderance of counterfeit drugs in Nigeria despite the laws. Data was gathered by a combination of the use of questionnaires and oral interviews. The results suggest that drug laws were adequate falling short only in their implementation. The task forces were rated as ineffective arising from corruption, communication gaps, lack of adequate funds, lack of vehicles, etc.

show abstract

Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México

Abstract: Accessibility and availability of drugs has been a matter of great concern for health services all over the world, especially for less developed countries. The World Health

Cited by 4 publications

References 2 publications

Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country

Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country

The fuzzy line between needs, coverage, and excess in the Mexican Formulary List: an example of qualitative market width analysis

Drug Regulation and Control in Nigeria: the Challenge of Counterfeit Drugs

Contact Info

Product

Resources

About